News

Most treatments for pain caused by knee osteoarthritis helped alleviate pain better than acetaminophen (Tylenol) – with one exception, according to a study published in the January 6 issue of the Annals of Internal Medicine

The prostate cancer medication leuprolide acetate (Lupron Depot), used in conjunction with acetylcholinesterase inhibitor (AChEI), slowed memory loss in female Alzheimer’s patients, according to a new study.

Resistance to the malaria medication artemisinin extends across much of Myanmar in Southeast Asia, according a new study, published online February 19 in The Lancet Infectious Diseases.

The VenaSeal system is newly approved to permanently treat varicose veins by sealing the affected veins using an adhesive agent, known as n-butyl-2-cyanoacrylate, which polymerizes into solid material after being injected into the vein.

Actavis has received final approval from FDA on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser's Subutex (buprenorphine 2 mg and 8 mg sublingual tablets) indicated for treatment of opioid dependence.

FDA approved Farydak (panobinostat) for the treatment of patients with multiple myeloma, which is attributed to 10,710 deaths in the U.S. annually.

FDA has authorized marketing of Bloom Syndrome carrier test, a direct-to-consumer genetic test from 23andMe.The test is designed to identify healthy individuals who carry a gene that could cause Bloom Syndrome in their offspring.

The introduction of high-cost, high-use PCSK9 inhibitors (proprotein convertase subtilisin/kexin 9) enzyme inhibitors to treat high cholesterol, takes the industry step closer to a future where “healthcare costs break the bank,” according to industry insiders.

New study findings suggest that an epigenetic test could be created to identify those individuals early in the process of developing diabetes mellitus, providing hope for preventing the disease.

In a move widely seen as a way to better compete with the other major chain drugstores, Rite Aid Corp. has announced an agreement on Feb. 11 to buy the pharmacy benefits manager (PBM) EnvisionRx for about $2 billion.